Hepion Pharmaceuticals’ Phase II ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

Hepion Pharmaceuticals, Inc. announced positive topline results from its recently completed Phase II ALTITUDE-NASH clinical trial by demonstrating improved physiologic liver function and was well tolerated after four months of treatment in subjects with stage 3 or greater fibrosis based on the AGILE 3+ criteria.